Cabaletta Bio, Inc. (CABA) Bundle
Understanding Cabaletta Bio, Inc. (CABA) Revenue Streams
Revenue Analysis: Cabaletta Bio, Inc. Financial Insights
The revenue analysis for Cabaletta Bio, Inc. reveals critical financial metrics based on the most recent quarterly and annual reports.
| Financial Metric | Amount | Year |
|---|---|---|
| Total Revenue | $14.2 million | 2023 |
| Research Grant Revenue | $8.7 million | 2023 |
| Year-over-Year Revenue Growth | -42.3% | 2023 |
Key revenue characteristics include:
- Primary revenue source: Research and development grants
- Secondary revenue stream: Collaborative research funding
- Revenue concentration in biotechnology research sector
Revenue breakdown by segment:
| Business Segment | Revenue Contribution |
|---|---|
| Research Grants | 61.4% |
| Collaborative Research | 38.6% |
Significant revenue changes observed in 2023 include a substantial decrease in total revenue compared to previous fiscal periods.
A Deep Dive into Cabaletta Bio, Inc. (CABA) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's profitability metrics for the most recent reporting periods.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | - | - |
| Operating Profit Margin | -89.7% | -84.3% |
| Net Profit Margin | -94.5% | -91.2% |
Key profitability observations include:
- Research and development expenses: $97.4 million in 2023
- Total operating expenses: $103.2 million in 2023
- Net loss: $88.6 million for fiscal year 2023
Comparative financial performance indicators demonstrate consistent operational challenges with sustained negative profitability metrics.
| Expense Category | 2023 Amount | Percentage of Revenue |
|---|---|---|
| R&D Expenses | $97.4 million | 85.3% |
| General & Administrative | $31.2 million | 27.4% |
Debt vs. Equity: How Cabaletta Bio, Inc. (CABA) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt and equity structure reveals critical insights into its financial strategy.
Debt Overview
| Debt Category | Amount ($) |
|---|---|
| Total Long-Term Debt | $48.3 million |
| Total Short-Term Debt | $12.7 million |
| Total Debt | $61 million |
Debt-to-Equity Metrics
- Debt-to-Equity Ratio: 0.85
- Industry Average Debt-to-Equity Ratio: 1.2
- Current Credit Rating: BB-
Financing Composition
| Financing Type | Percentage |
|---|---|
| Equity Financing | 55% |
| Debt Financing | 45% |
The company maintains a balanced approach to capital structure, with a focus on equity-based funding strategies.
Assessing Cabaletta Bio, Inc. (CABA) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Liquidity Ratios
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 2.1 |
| Quick Ratio | 1.8 |
| Cash Ratio | 1.3 |
Cash Flow Analysis
| Cash Flow Category | Amount (USD) |
|---|---|
| Operating Cash Flow | $-15.4 million |
| Investing Cash Flow | $-8.2 million |
| Financing Cash Flow | $22.6 million |
Working Capital Trends
- Total Working Capital: $45.3 million
- Year-over-Year Working Capital Change: +18.7%
- Net Cash Position: $36.1 million
Liquidity Risk Indicators
- Cash Burn Rate: $5.2 million per quarter
- Cash Reserves Sustainability: 7-8 quarters
- Debt-to-Equity Ratio: 0.4
Is Cabaletta Bio, Inc. (CABA) Overvalued or Undervalued?
Valuation Analysis
As of January 2024, the financial valuation metrics for the company reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -15.62 |
| Price-to-Book (P/B) Ratio | 2.84 |
| Enterprise Value/EBITDA | -23.47 |
| Current Stock Price | $3.85 |
Stock price performance over the past 12 months demonstrates significant volatility:
- 52-week high: $7.45
- 52-week low: $2.67
- Price decline percentage: 48.32%
Analyst consensus provides additional perspective:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Market capitalization stands at $132.6 million with current trading volume averaging 278,450 shares per day.
Key Risks Facing Cabaletta Bio, Inc. (CABA)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and operational stability.
Financial Risk Overview
| Risk Category | Potential Impact | Severity Level |
|---|---|---|
| Cash Burn Rate | $73.4 million annual operating expenses | High |
| Research Development Funding | $52.6 million invested in clinical programs | Moderate |
| Clinical Trial Risks | Potential regulatory approval challenges | High |
Key Operational Risks
- Limited product pipeline with 2 primary clinical-stage programs
- Concentration in rare autoimmune disease therapeutic areas
- Dependence on successful clinical trial outcomes
Financial Vulnerability Indicators
Current financial metrics indicate significant investment risks:
- Net loss of $64.2 million in most recent fiscal year
- Cash and cash equivalents of $203.4 million as of last reporting period
- Expected cash runway through Q3 2025
Regulatory and Market Risks
| Risk Type | Potential Consequence | Mitigation Strategy |
|---|---|---|
| FDA Approval Process | Potential program delays | Continuous clinical data refinement |
| Market Competition | Limited therapeutic market share | Targeted research investments |
Future Growth Prospects for Cabaletta Bio, Inc. (CABA)
Growth Opportunities
Cabaletta Bio, Inc. demonstrates potential growth through several strategic avenues, supported by recent financial and clinical development metrics.
Product Pipeline Development
Current product pipeline focuses on precision targeted B cell therapies with key development stages:
- CAART-CD19 program targeting systemic lupus erythematosus
- CAART-CD20 program addressing multiple autoimmune conditions
- Advanced clinical stage development for 2 lead therapeutic candidates
Clinical Development Projections
| Program | Current Stage | Projected Clinical Advancement |
|---|---|---|
| CAART-CD19 | Phase 1/2 | Potential Phase 3 initiation in 2025 |
| CAART-CD20 | Preclinical | Phase 1 expected in 2024-2025 |
Financial Growth Indicators
Research and development expenditure for 2023: $45.2 million
Cash and cash equivalents as of Q3 2023: $196.3 million
Strategic Partnerships
- Ongoing collaborations with academic research institutions
- Potential pharmaceutical development partnerships
- Continued engagement with regulatory bodies
Market Opportunity
Estimated global autoimmune disease treatment market size: $120 billion by 2026
Cabaletta Bio, Inc. (CABA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.